Experts Discuss Advances in the Use of BTK Inhibitors for the Treatment of Relapsed/Refractory MCL

Experts Discuss Advances in the Use of BTK Inhibitors for the Treatment of Relapsed/Refractory MCL is organized by Clinical Care Options (CCO), LLC.,Released: March 20, 2023,Expiration: March 19, 2024,Program Learning Goal:,The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in selecting individualized treatments for patients with relapsed/refractory MCL.,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Evaluate emerging BTK inhibitor data in the treatment of MCL considering the potential impact of safety and efficacy results on clinical practice,• Plan BTKi-based therapeutic strategies for patients with R/R MCL, taking into consideration global indications and recent practice-changing clinical trial results,• Select and sequence therapy for patients with MCL who have developed resistance to or intolerance of covalent BTKi-based therapy to optimize clinical outcomes,• Identify patients with MCL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations